Introduction: Mild cognitive impairment: beyond controversies, towards a consensus
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The concept of mild cognitive impairment (MCI) has received a considerable amount of interest during the last years, especially as a possible prodromal phase of Alzheimer's disease (AD). AD has a long preclinical period, which presents an opportunity for identifying subjects in a phase when pathology has already begun but AD diagnosis is not achievable. Early diagnosis of AD is important to initiate symptomatic treatment, and will be of even greater significance if medications that might delay or halt the dementia process become available. Furthermore, better identification of elderly persons at high risk of future dementia will provide doctors with opportunities for prognostic counselling, and improve health care planning. Due to the worldwide ageing phenomenon, dementia and MCI have growing public health relevance. There is emerging evidence suggesting a high prevalence of cognitive impairment even in younger ages. For all these reasons, the concept of MCI is useful both clinically and as a research entity. However, as the literature of MCI has expanded there has been confusion concerning the specific boundaries of the condition, and controversies regarding its definition, assessment, management and intervention strategies. A greater consensus and standardization of definitions and research methodology for MCI in needed to make further studies more comparable and useful for designing intervention strategies. Persons with MCI are known to have an increased risk of progressing to dementia compared to elderly persons with normal levels of cognitive functioning. However, the evolution is heterogeneous, as some persons have been seen to improve over time, whereas others have an increased risk of mortality. To date, much of the research on MCI has derived from clinical sources, with the focus on symptomatic patients within specialized medical settings, although there are increasing results emerging from population-based sources. The aim of the first Key Symposium was to combine the clinical perspectives with epidemiological evidence to reach a consensus concerning a broader concept of MCI and to identify future research questions. This symposium brought together both a multidisciplinary and a worldwide group of experts to focus solely on this subject. A group of 100 international physicians and researchers from Asia, Australia, Europe and the US met in Stockholm. Five aspects of MCI were covered and presented as articles in this issue, reflecting the authors’ perspectives of the current state of the art: clinical presentation [1], cognitive assessment and markers [2], neuroimaging [3], biomarkers [4] and genetics [5]. The meeting concluded with a general discussion followed by a day of deliberations involving the speakers, discussants, chairpersons and the symposium's Scientific Committee. This resulted in a report from this international working group, describing the state of the art of MCI, recommendations for management and treatment, and future research questions [6]. The main questions addressed by the working group included whether MCI represents a useful clinical and research entity, as well as the challenge of further refining the criteria so that treatments can be targeted towards a specific MCI population. No conflict of interest was declared.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Self-citationCSF biomarkers for mild cognitive impairment
Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151
Cited by
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Mild Cognitive Impairment as a Clinical Entity and Treatment Target
Petersen, R. C., & Morris, J. C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1160 · Cited by 935
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785
“A ninth 4 homozygote (age 73 years) developed subjective and neuropsychological evidence of cognitive decline in the 2 years between her last 2 clinical visits, and she was diagnosed with amnestic MCI (38) 7 months before her PiB PET scan.”
BackgroundMild Cognitive Impairment:An Overview
Petersen, R. C., & Negash, S. (2008) · CNS Spectrums · doi:10.1017/s1092852900016151 · Cited by 667
The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive Impairment
Tarawneh, R., & Holtzman, D. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006148 · Cited by 471
Metadata
- Authors
- B, W., K, P., M, K., V, J., & L, F.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2004-08-20
- Volume
- 256
- Issue
- 3
- Pages
- 181-182
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W1968080096
- Cited by
- 107
- References
- 2
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Introduction: Mild cognitive impairment: beyond controversies, towards a consensus. https://app.cochat.ai/papers/10.1111/j.1365-2796.2004.01382.x
- The paper
- B, W., K, P., M, K., V, J., & L, F. (2004). Introduction: Mild cognitive impairment: beyond controversies, towards a consensus. Journal of Internal Medicine. https://doi.org/10.1111/j.1365-2796.2004.01382.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.